Document is current
Any future updates will be listed below
-
Authors
Bleibtreu, Alexandre
Bennis, Youssef
Dinh, Aurélien https://orcid.org/0000-0002-5843-4819
Dupont, Hervé
Friggeri, Arnaud
Jeannot, Katy
Kipnis, Eric
Zahar, Jean-Ralph
,
-
Funding
Funding for this research was provided by:
Shionogi
- License Information
-
More Information
Article History
Received: 28 September 2025
Accepted: 8 January 2026
First Online: 31 January 2026
Declarations
:
: Aurélien Dinh reports consulting fees from Shionogi Eumedica, Pfizer, and Advanz Pharma. Katy Jeannot reports research funding from Thermo Fisher Scientific, MSD, Shionogi, Pfizer, bioMerieux, and Bacteriomic. Eric Kipnis reports consulting fees from Shionogi, Advanz, LFB Biomedicaments, Astra Zeneca, Pfizer, and MSD. Jean-Ralph Zahar reports consulting fees from Pfizer and Shionogi. Alexandre Bleibtreu reports consulting fees from Advanz, Pfizer, Eumedica, and Shionogi. Youssef Bennis reports consulting fees from Shionogi and Novartis. Hervé Dupont reports consulting fees from Pfizer, Gilead, MSD, Mundipharma, Shionogi, and Paratek. Arnaud Friggeri reports consulting fees from Shionogi.
: Institutional review board approval was not required, as the study did not involve patient data and no database was established. All nine panel participants consented to participate and to the publication. However, one participant requested not to be included among the authors for personal reasons. Data from the REA-REZO ( ) and GERPA networks are identifiable and permission is required for access.
